Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, Genomics and Phylogenetic Studies, and RNA Research and Splicing.
Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration.
SWI/SNF chromatin remodeling factor BRAHMA promotes de novo shoot regeneration by epigenetic priming via H3K27me3 removal.
Structural robustness and temporal vulnerability of the starvation-responsive metabolic network in healthy and obese mouse liver.
Supplementary Figure S1 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Supplementary Figure S3 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Supplementary Figure S4 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Supplementary Figure S8 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Supplementary Figure S7 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Supplementary Figure S5 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Supplementary Figure S9 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Supplementary Figure S6 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Table S1 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Supplementary Figure S2 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
Data from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
CD106 in Tumor-Specific Exhausted CD8+ T Cells Mediates Immunosuppression by Inhibiting TCR Signaling.
TableS2 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Figure S5 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Figure S7 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
TableS5 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Figure S1 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Figure S2 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Data from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Figure S2 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Figure S4 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
TableS5 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
TableS4 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Supplementary Table S6 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Supplementary Table S6 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Figure S7 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling
Figure S4 from CD106 in Tumor-Specific Exhausted CD8<sup>+</sup> T Cells Mediates Immunosuppression by Inhibiting TCR Signaling